カジノシークレット has agreed to settle with Shenzhou Biology and Technology Co., Ltd. in the U.S. Patent infringement lawsuit relating to oxidized coenzyme Q10

カジノシークレット (Minato, Tokyo, Japan; President: Mamoru Kadokura) has been in dispute with Xiamen Kingdomway Group Company, Pacific Rainbow International Inc., and Shenzhou Biology and Technology Co., Ltd. since March 2011, when Kaneka instituted a patent infringement action against the companies in the United States District Court for the Central District of California alleging infringement of Kaneka’s U.S. Patent No. 7,910,340 relating to coenzyme Q10(Kaneka Q10).

In April 2014, the US District Court for the Central District of California granted the Defendants’ motions for the summary judgement and denied ロサンゼルスカジノ’s motion for summary judgement, but after and appeal by ロサンゼルスカジノ, the Federal Circuit Court of Appeals remanded the case to District Court in June, 2015.

On November 5, 2017, ロサンゼルスカジノ agreed to settle with Shenzhou Biology and Technology Co., Ltd. and the parties agreed to establish comprehensive arrangements for future business. The two parties have agreed that ロサンゼルスカジノ will distribute Shenzhou’s Q10 in North America as one of its channels and that Shenzhou will distribute ロサンゼルスカジノ’s Ubiquinol product in China. We will increase a share of the oxidized coenzyme Q10 market in North America and expand Ubiquinol market in China through this agreement.

ロサンゼルスカジノ continues the dispute with Xiamen Kingdomway Group Company and Pacific Rainbow International Inc., for the District Court case in the Central District of California and with Zhejiang Medicine Co. Ltd and ZMC-USA, LLC for the similar case in Texas.